EUVIMEDEUVIMED entdecken
Crossref

Risk Factors, Antithrombotic Management, and Long-Term Outcomes of Patients Undergoing Endovascular Treatment of Unruptured Intracranial Aneurysms

Yanxiao Xiang, Ping Zhang, Yongjie Lai, Donghai Wang, Anchang Liu

Thrombosis and Haemostasis · 01.01.2025 · 125 (01) · 058-068

DOI: 10.1055/a-2347-4221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.01.2025. Verfasst von Yanxiao Xiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Intracranial Aneurysm, Endovascular Procedures, Platelet Aggregation Inhibitors, Tirofiban. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients receiving endovascular treatment for unruptured intracranial aneurysms (UIAs) face varying risks and benefits with antithrombotic management. This study aimed to evaluate the perioperative and long-term effects of antithrombotic strategies, identify the populations that would benefit, and explore the predictive factors affecting the long-term outcomes.

Methods

UIA patients undergoing endovascular treatment including stent-assisted coiling or flow diversion between June 2019 and June 2022 were enrolled. We compared perioperative and long-term complications between tirofiban and dual antiplatelet therapy groups. Optimal candidates for each antithrombotic treatment were identified using multivariate logistic regression. Nomograms were developed to determine the significant predictors for thromboembolic complications during follow-up.

Results

Among 181 propensity-score matched pairs, the tirofiban group showed a trend toward a lower rate of thromboembolic complications than the DAPT group without elevating major bleeding risk in either period. Homocysteine (Hcy) level ≥10 μmol/L was a significant independent factor associated with thromboembolic complication in both periods. Subgroup analysis highlighted that in patients with high Hcy levels, tirofiban and sustained antiplatelet treatment for ≥12 months were protective factors, while a history of stroke was an independent risk factor for thromboembolic events in follow-up. Four variables were selected to construct a prognostic nomogram, history of hypertension, prior stroke, Hcy level, and the duration of antiplatelet therapy.

Conclusion

Perioperative low-dose tirofiban and extended antiplatelet therapy demonstrated a favorable trend in long-term outcomes for UIA patients with preoperative Hcy levels ≥10 μmol/L undergoing endovascular treatment. The prognostic model offers reliable risk prediction and guides antithrombotic strategy decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intracranial AneurysmEndovascular ProceduresPlatelet Aggregation InhibitorsTirofibanFibrinolytic AgentsHumansMaleFemaleMiddle AgedRisk FactorsAgedTreatment OutcomeRetrospective StudiesTime FactorsRisk AssessmentDual Anti-Platelet TherapyThromboembolismStentsNomogramsAdult

Substanzen

Platelet Aggregation InhibitorsTirofibanFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Haidian District, Beijing, China.
  • Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
  • Department of Pharmacy, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China.

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Xiang, Y., Zhang, P., Lai, Y., Wang, D., & Liu, A. (2025). Risk Factors, Antithrombotic Management, and Long-Term Outcomes of Patients Undergoing Endovascular Treatment of Unruptured Intracranial Aneurysms. Thrombosis and Haemostasis, 125(01), 058-068. https://doi.org/10.1055/a-2347-4221

Vancouver

Xiang Y, Zhang P, Lai Y, Wang D, Liu A. Risk Factors, Antithrombotic Management, and Long-Term Outcomes of Patients Undergoing Endovascular Treatment of Unruptured Intracranial Aneurysms. Thrombosis and Haemostasis. 2025;125(01):058-068. doi:10.1055/a-2347-4221

BibTeX
@article{Xiang2025,
  author = {Xiang, Yanxiao and Zhang, Ping and Lai, Yongjie and Wang, Donghai and Liu, Anchang},
  title = {Risk Factors, Antithrombotic Management, and Long-Term Outcomes of Patients Undergoing Endovascular Treatment of Unruptured Intracranial Aneurysms},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {01},
  pages = {058--068},
  doi = {10.1055/a-2347-4221}
}
Kostenlos starten →